Lead Product(s) : CYWC628
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : FibroBiologics
Deal Size : Undisclosed
Deal Type : Collaboration
FibroBiologics and Charles River Partner for Fibroblast Cell-Based Therapies
Details : The collaboration aims to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for diabetic foot ulcer (DFU).
Brand Name : CYWC628
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 18, 2024
Lead Product(s) : CYWC628
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : FibroBiologics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme,Dehydrated Human Amnion Membrane
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : MediWound
Deal Size : Undisclosed
Deal Type : Collaboration
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
Details : Under the collaboration, MIMEDX will provide its market leading placental tissue allograft EPIFIX® to be used during the wound healing phase of the EscharEx® (concentrate of proteolytic enzymes enriched in bromelain) Phase III study in venous leg ulcer...
Brand Name : EscharEx
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 15, 2023
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme,Dehydrated Human Amnion Membrane
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : MediWound
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cannabidiol
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cannabidiol is a topical CB1 receptor negative allosteric modulator (NAM), which is being evaluated in phase 1 clinical studies for the treatment of Diabetic Foot.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cymerus mesenchymal stem cells
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers
Details : This will be the first clinical trial to utilise CYP-006TK, a polymer-coated silicon dressing (seeded with Cymerus MSCs) that Cynata has licensed from TekCyte Pty Ltd (TekCyte).
Brand Name : CYP-006TK
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 30, 2021
Lead Product(s) : Cymerus mesenchymal stem cells
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cymerus mesenchymal stem cell
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte
Details : Cynata plans to undertake a clinical trial of its Cymerus MSC product in patients with diabetic foot ulcers based on this solid pre-clinical foundation and utilising the TekCyte technology.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 01, 2021
Lead Product(s) : Cymerus mesenchymal stem cell
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?